2014 Archived Content

Short Courses*

(click on 'Learn More' next to each course title for instructor photos, bios and additional course information)

TUESDAY, April 22

Morning Course | 8:00 – 11:00 AM

SC1: Trends in Physical Properties of Drugs - Learn More 

Instructors: Terry Stouch, Ph.D., President, R&D, Science for Solutions, LLC

Robert Fraczkiewicz, Ph.D., Team Leader, Simulations Plus, Inc.

Geoff Skillman, M.D., Ph.D., Senior Vice President, Research, OpenEye Scientific Software

Yvonne Martin, Ph.D., Computer-Assisted Drug Design Specialist; Principal, Yvonne Martin Consulting

John Comer, Ph.D., CSO, Sirius Analytical Ltd.

  • Properties important for enhanced efficacy, delivery, and formulation
  • pKa, tautomerism, crystallization, others
  • Computational prediction: What works - what doesn’t
  • Experimental best practices

Noon Courses | 12:00 – 3:00 PM

SC2: GPCR Structure-Based Drug Discovery - Learn More 

Vsevolod (Seva) Katritch, Ph.D., Assistant Professor, Integrative Structural and Computational Biology, The Scripps Research Institute
Jan Steyaert, Ph.D., Director, Structural Biology Brussels Research Center, Vrije University Brussels

  • Review of recent structures and their lessons
  • Working with fragments
  • Dealing with conformational states
  • Antibodies as probes for structure

SC3: Epigenetic Assays and High-Throughput Screening - Learn More 

Instructors: Abdellah Allali-Hassani, Ph.D., Team Leader, Enzymatic Assays, Structural Genomics Consortium, University of Toronto
Karen Maegley, Ph.D., Associate Research Fellow, Integrative Biology and Biochemistry, Oncology, Pfizer, Inc.
Daniel K. Treiber, Ph.D., Senior Director, Research & Development, KINOMEscan Division, DiscoveRx Corporation

  • Overview of current screening strategies for hits
  • Development of biochemical/biophysical assays
  • Development of phenotypic/cell-based assays
  • Application to Histone Methyltransferases, Demethylases & BET bromodomain

Afternoon Courses | 3:30 – 6:30 PM


SC5: Immunology Basics for Chemists - Learn More  


Heba Nowyhed, Ph.D., Postdoctoral Fellow, Laboratory of Catherine Hedrick, Inflammation Biology, La Jolla Institute for Allergy and Immunology

Duygu Sag, Ph.D., Postdoctoral Fellow, Laboratory of Catherine Hedrick, Inflammation Biology, La Jolla Institute for Allergy and Inflammation

Seng-Lai “Thomas” Tan, Ph.D., Head, Cellular and Translational Immunology, EMD Serono Research and Development Institute, Inc.

  • Review of immune system’s cellular players
  • Review of inflammatory process
  • Autoimmune & inflammation-related diseases
  • Current treatment landscape and promising drug targets

SC6: Molecular Interactions and Drug Design - Learn More 

Instructor: Maricel Torrent, Ph.D., Senior Scientist, AbbVie

  • Drug design principles generally applicable to all medicinal chemistry programs
  • Interpretation of atomic-level protein X-ray and modeled structures of binding modes
  • Understanding the relative amounts of potency gain from different interactions
  • Case studies illustrate all of the design strategies

Dinner Course | 6:30 – 8:30 PM

SC7: Pharmacophore Discovery and Modeling Using Extended Hückel Theory - Learn More 

Instructor: Chris Williams, Ph.D., Principal Scientist, Chemical Computing Group

  • Building pharmacophore models/queries
  • Generating and using 3D information to search for novel active compounds
  • Advantages of using Extended Hückel Theory (EHT), a semi-empirical method that takes into account electron donating and withdrawing effects for a given chemical structure
  • Kinase-based case studies

THURSDAY Dinner Courses | 6:30 – 9:00 PM

SC8: Enabling Macrocyclic Compounds for Drug Discovery: Opportunities, Challenges and Strategies - Learn More 

Instructors: Mark L. Peterson, Ph.D., Chief Operating Officer, Cyclenium Pharma Inc.
Eric Marsault, Ph.D., Professor, Pharmacology, University of Sherbrooke

  • Unique characteristics of macrocycles
  • Synthesizing and screening macrocyclic compound libraries
  • Pros and cons of each methodology
  • Drug discovery and development examples and challenges for macrocyclic molecules

SC9: Advancing Tools and Technologies for Fragment-Based Design - Learn More 

Instructors: Daniel A. Erlanson, Ph.D., Co-Founder, Carmot Therapeutics, Inc.
Edward R. Zartler, Ph.D., President & CSO, Quantum Tessera Consulting

  • Why fragments – pros and cons?
  • What makes a good fragment?
  • What to do with a fragment – growing, linking, and more
  • Design of fragment libraries
  • Importance of using orthogonal/multiple screening methods

SC10: Introduction to Targeted Covalent Inhibitors - Learn More 


Brion W. Murray, Ph.D., Research Fellow, Pfizer Oncology

Christoph Zapf, Ph.D., Principal Scientist, Worldwide Medicinal Chemistry, Pfizer Research Labs


Panelist: Erik Verner, Ph.D., Director, Chemistry, Principia Biopharma

  • Overview of covalent drugs, irreversible and reversible inhibitors including recent clinical examples
  • Biochemical analysis of covalent inhibitors
  • Design considerations for targeted covalent inhibitors
  • De-risking covalent inhibitors
  • Mechanism of drug resistance
  • Panel discussion/Q&


*Separate registration is required